AtaiBeckley Inc. 4

Andrea Heslin Smiley had all 4,666 common shares and 455,968 option-based shares in AtaiBeckley Inc. cashed out and converted into cash plus CVRs upon Eli Lilly’s acquisition closing on 2026-09-11.

On September 11, 2026, in connection with the closing of Eli Lilly and Company’s acquisition of AtaiBeckley Inc., all of Andrea Heslin Smiley’s equity in AtaiBeckley was cancelled and cashed out. Her 4,666 outstanding shares of common stock were converted into the right to receive $6.75 per share in cash plus one contingent value right (CVR) per share, with each CVR representing potential additional cash payments of up to $2.50 upon specified clinical and regulatory milestones. Concurrently, six tranches of stock options with exercise prices ranging from $1.34 to $4.50 and covering a total of 455,968 underlying shares (64,000 + 64,000 + 103,000 + 103,000 + 121,968) were cancelled and converted into the right to receive cash equal to the intrinsic value of each option (the excess of $6.75 over the respective strike price multiplied by the number of option shares) plus one CVR for each underlying share, regardless of vesting. Following the merger, Smiley no longer holds AtaiBeckley equity securities, as the company became a wholly owned subsidiary of Eli Lilly.

Filing Facts

CIK

2081043

Ticker

ATAI

Form

4

Source Type

fda

Accession

0001140361-26-036381

Alert Tier

5